曲普瑞林对女童特发性中枢性性早熟的临床有效性及安全性综合评价

摘要

Objectives:To observe and explore the effect and safety of Triptorelin on girls with Idiopathic central precocious puberty (ICPP).Methods:48 girls with ICPP in the hospital from August 201 1 to August 2013 were selected;all the girls received intramuscular injection of triptorelin therapy.Bone age (BA),predicted adult height (PAH),body mass index (BMI),bone age height standard deviation score (HtSDSBA)and growth rate were recorded and compared before and after treatment.Gonadotropin-releasing hormone (GnRH)stimulate test was carried out to detect the level of estradiol (E2),luteinizing hormone (LH)and follicle stimulating hormone (FSH).Results:BA,PAH,BMI and HtSDSBA were (10.2 ±0.2)years old,(154.8 ±4.2)cm,(16.0 ± 0.6)kg/m2,and (2.7 ±0.7)cm before treatment,after treatment these were (10.6 ±0.2)years,(159.1 ± 5.0)cm,(17.6 ±0.8)kg/m2 and (1.9 ±0.6)cm,respectively.The difference was statistically significant (P<0.05);the difference of growth rate at 0-6 months,7-12 months and 13-24 months before and after treat-ment was not statistically significant (P>0.05);LH,FSH and E2 levels were (22.8 ±1.8)IU /L ,(15.8 ± 4.2)IU /L and (54.3 ±17.6)ng /L in GnRH stimulation test before treatment.After treatment these were (1.4 ±0.2)IU /L,(2.7 ±0.8)IU /L and (11.3 ±2.9)ng/L respectively.The difference was statistically signifi cant (P<0.05).Conclusion:Triptorelin therapy has a significant effect for ICPP girls.It can help slow down bone age maturation and ultimately achieve the desired height.%目的：对曲普瑞林治疗女童特发性中枢性性早熟（Idiopathic central precocious puberty， ICPP）的临床疗效进行观察并探讨。方法：选择本医院自2011年8月至2013年8月接诊的ICPP女童患儿48例，对患儿肌肉注射曲普瑞林进行治疗。治疗前后统计患儿骨龄（BA）、预测成年身高（PAH）、体质量指数（BMI）、骨龄身高标准差分值（HtSDSBA）以及生长速率，并进行促性腺激素释放激素（GnRH）激发试验测定患儿雌二醇（E2）、促黄体生成素（LH）和卵泡刺激素（FSH）水平。结果：治疗前患儿BA、PAH、BMI和HtSDSBA分别为（10.2±0.2）岁、（154.8±4.2）cm、（16.0±0.6）kg／m2和（2.7±0.7）cm，治疗后分别为（10.6±0.2）岁、（159.1±5.0）cm、（17.6±0.8）kg／m2和（1.9±0.6）cm，治疗前后差异具有统计学意义（P＜0.05）；治疗前后0～6个月、7～12个月和13～24个月的生长速率相比，差异不具有统计学意义（P＞0.05）；治疗前GnRH激发试验中LH、FSH和E2的水平分别为（22.8±1.8）IU／L、（15.8±4.2）IU／L和（54.3±17.6）ng／L，治疗后为（1.4±0.2）IU／L、（2.7±0.8）IU／L和（11.3±2.9）ng／L，治疗前后差异具有统计学意义（P＜0.05）。结论：曲普瑞林治疗女童ICPP的疗效显著，有助于延缓骨龄成熟，从而达到理想身高。